Loading…

Factors associated with hematological adverse reactions of drugs authorized via the centralized procedure

Serious hematological adverse drug reactions (HADRs) may lead to or prolong hospitalization and even cause death. The aim of this study was to determine the regulatory factors associated with HADRs caused by drugs that were authorized up to July 2023 by the European Medicines Agency (EMA) and to eva...

Full description

Saved in:
Bibliographic Details
Published in:Scientific reports 2024-04, Vol.14 (1), p.9074-9074, Article 9074
Main Authors: Stević, Ivana, Janković, Slobodan M., Georgiev, Andrijana Milošević, Marinković, Valentina, Lakić, Dragana
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c492t-2dce4497e6319548c0804f0d634babb08ff8e7b0c3f443a82f5aa6548955fe973
container_end_page 9074
container_issue 1
container_start_page 9074
container_title Scientific reports
container_volume 14
creator Stević, Ivana
Janković, Slobodan M.
Georgiev, Andrijana Milošević
Marinković, Valentina
Lakić, Dragana
description Serious hematological adverse drug reactions (HADRs) may lead to or prolong hospitalization and even cause death. The aim of this study was to determine the regulatory factors associated with HADRs caused by drugs that were authorized up to July 2023 by the European Medicines Agency (EMA) and to evaluate the frequency of HADRs. Using a cross-sectional approach, the type and frequency of HADRs were collected from the Summaries of Product Characteristics of Drugs Authorized by the EMA and analyzed within proprietary, nonproprietary, and biosimilar/biological frameworks. Multivariate statistical analysis was used to investigate the associations of generic status, biosimilar status, conditional approval, exceptional circumstances, accelerated assessment, orphan drug status, years on the market, administration route, and inclusion on the Essential Medicines List (EML) with HADRs. In total, 54.78% of proprietary drugs were associated with HADRs at any frequency, while anemia, leucopenia, and thrombocytopenia were observed in approximately 36% of the patients. The predictors of any HADR, anemia, and thrombocytopenia of any frequency are generic status, biosimilar status, and inclusion on the EML, while the only protective factor is the administration route. Biosimilars and their originator biologicals have similar frequencies of HADRs; the only exception is somatropin. Knowledge of the regulatory factors associated with HADRs could help clinicians address monitoring issues when new drugs are introduced for the treatment of patients.
doi_str_mv 10.1038/s41598-024-59710-3
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_573b72eb51fe43389533fe16724f3796</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_573b72eb51fe43389533fe16724f3796</doaj_id><sourcerecordid>3042217372</sourcerecordid><originalsourceid>FETCH-LOGICAL-c492t-2dce4497e6319548c0804f0d634babb08ff8e7b0c3f443a82f5aa6548955fe973</originalsourceid><addsrcrecordid>eNp9ks1u1DAUhSMEolXpC7BAkdiwCdi-dhyvEKooVKrEBtaW41xnPMrEg-0MgqfHnQylZYE3tu79zvHfqaqXlLylBLp3iVOhuoYw3gglKWngSXXOCBcNA8aePlifVZcpbUkZgilO1fPqDLqWQwHOK39tbA4x1SalYL3JONQ_fN7UG9yZHKYwemum2gwHjAnriAX3YU51cPUQl7EIl7wJ0f8qwoM3dd5gbXHO0UzH2j4Gi8MS8UX1zJkp4eVpvqi-XX_8evW5uf3y6ebqw21juWK5YYNFzpXEFqgSvLOkI9yRoQXem74nnXMdyp5YcJyD6ZgTxrQFVEI4VBIuqpvVdwhmq_fR70z8qYPx-lgIcdQmZm8n1EJCLxn2gjrkAMUCwCFtJeMOpGqL1_vVa7_0OxxO93pk-rgz-40ew0HT8kcMgBaHNyeHGL4vmLLe-WRxmsyMYUkaCAcimTqir_9Bt2GJc3mrO4oxKkGyQrGVsjGkFNHdn4YSfZcMvSZDl2ToYzI0FNGrh_e4l_zJQQFgBVJpzSPGv3v_x_Y3MNbEoQ</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3042217372</pqid></control><display><type>article</type><title>Factors associated with hematological adverse reactions of drugs authorized via the centralized procedure</title><source>Publicly Available Content (ProQuest)</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><source>Springer Nature - nature.com Journals - Fully Open Access</source><creator>Stević, Ivana ; Janković, Slobodan M. ; Georgiev, Andrijana Milošević ; Marinković, Valentina ; Lakić, Dragana</creator><creatorcontrib>Stević, Ivana ; Janković, Slobodan M. ; Georgiev, Andrijana Milošević ; Marinković, Valentina ; Lakić, Dragana</creatorcontrib><description>Serious hematological adverse drug reactions (HADRs) may lead to or prolong hospitalization and even cause death. The aim of this study was to determine the regulatory factors associated with HADRs caused by drugs that were authorized up to July 2023 by the European Medicines Agency (EMA) and to evaluate the frequency of HADRs. Using a cross-sectional approach, the type and frequency of HADRs were collected from the Summaries of Product Characteristics of Drugs Authorized by the EMA and analyzed within proprietary, nonproprietary, and biosimilar/biological frameworks. Multivariate statistical analysis was used to investigate the associations of generic status, biosimilar status, conditional approval, exceptional circumstances, accelerated assessment, orphan drug status, years on the market, administration route, and inclusion on the Essential Medicines List (EML) with HADRs. In total, 54.78% of proprietary drugs were associated with HADRs at any frequency, while anemia, leucopenia, and thrombocytopenia were observed in approximately 36% of the patients. The predictors of any HADR, anemia, and thrombocytopenia of any frequency are generic status, biosimilar status, and inclusion on the EML, while the only protective factor is the administration route. Biosimilars and their originator biologicals have similar frequencies of HADRs; the only exception is somatropin. Knowledge of the regulatory factors associated with HADRs could help clinicians address monitoring issues when new drugs are introduced for the treatment of patients.</description><identifier>ISSN: 2045-2322</identifier><identifier>EISSN: 2045-2322</identifier><identifier>DOI: 10.1038/s41598-024-59710-3</identifier><identifier>PMID: 38643204</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>631/154/1438 ; 631/154/155 ; 692/499 ; 692/700/155 ; 692/700/478/174 ; 692/700/565/2194 ; Anemia ; Anemia - chemically induced ; Anemia - drug therapy ; Biological products ; Biosimilar Pharmaceuticals - adverse effects ; Centralized procedure ; Drug Approval ; Drug-Related Side Effects and Adverse Reactions - epidemiology ; Drug-Related Side Effects and Adverse Reactions - etiology ; Drugs ; Drugs, Essential ; Drugs, Generic ; Hematological adverse drug reaction ; Hematology ; Humanities and Social Sciences ; Humans ; Leukopenia ; Leukopenia - chemically induced ; multidisciplinary ; Pharmaceutical Preparations ; Regulatory factors ; Science ; Science (multidisciplinary) ; Side effects ; Statistical analysis ; Thrombocytopenia ; Thrombocytopenia - chemically induced</subject><ispartof>Scientific reports, 2024-04, Vol.14 (1), p.9074-9074, Article 9074</ispartof><rights>The Author(s) 2024</rights><rights>2024. The Author(s).</rights><rights>The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c492t-2dce4497e6319548c0804f0d634babb08ff8e7b0c3f443a82f5aa6548955fe973</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/3042217372/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/3042217372?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38643204$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Stević, Ivana</creatorcontrib><creatorcontrib>Janković, Slobodan M.</creatorcontrib><creatorcontrib>Georgiev, Andrijana Milošević</creatorcontrib><creatorcontrib>Marinković, Valentina</creatorcontrib><creatorcontrib>Lakić, Dragana</creatorcontrib><title>Factors associated with hematological adverse reactions of drugs authorized via the centralized procedure</title><title>Scientific reports</title><addtitle>Sci Rep</addtitle><addtitle>Sci Rep</addtitle><description>Serious hematological adverse drug reactions (HADRs) may lead to or prolong hospitalization and even cause death. The aim of this study was to determine the regulatory factors associated with HADRs caused by drugs that were authorized up to July 2023 by the European Medicines Agency (EMA) and to evaluate the frequency of HADRs. Using a cross-sectional approach, the type and frequency of HADRs were collected from the Summaries of Product Characteristics of Drugs Authorized by the EMA and analyzed within proprietary, nonproprietary, and biosimilar/biological frameworks. Multivariate statistical analysis was used to investigate the associations of generic status, biosimilar status, conditional approval, exceptional circumstances, accelerated assessment, orphan drug status, years on the market, administration route, and inclusion on the Essential Medicines List (EML) with HADRs. In total, 54.78% of proprietary drugs were associated with HADRs at any frequency, while anemia, leucopenia, and thrombocytopenia were observed in approximately 36% of the patients. The predictors of any HADR, anemia, and thrombocytopenia of any frequency are generic status, biosimilar status, and inclusion on the EML, while the only protective factor is the administration route. Biosimilars and their originator biologicals have similar frequencies of HADRs; the only exception is somatropin. Knowledge of the regulatory factors associated with HADRs could help clinicians address monitoring issues when new drugs are introduced for the treatment of patients.</description><subject>631/154/1438</subject><subject>631/154/155</subject><subject>692/499</subject><subject>692/700/155</subject><subject>692/700/478/174</subject><subject>692/700/565/2194</subject><subject>Anemia</subject><subject>Anemia - chemically induced</subject><subject>Anemia - drug therapy</subject><subject>Biological products</subject><subject>Biosimilar Pharmaceuticals - adverse effects</subject><subject>Centralized procedure</subject><subject>Drug Approval</subject><subject>Drug-Related Side Effects and Adverse Reactions - epidemiology</subject><subject>Drug-Related Side Effects and Adverse Reactions - etiology</subject><subject>Drugs</subject><subject>Drugs, Essential</subject><subject>Drugs, Generic</subject><subject>Hematological adverse drug reaction</subject><subject>Hematology</subject><subject>Humanities and Social Sciences</subject><subject>Humans</subject><subject>Leukopenia</subject><subject>Leukopenia - chemically induced</subject><subject>multidisciplinary</subject><subject>Pharmaceutical Preparations</subject><subject>Regulatory factors</subject><subject>Science</subject><subject>Science (multidisciplinary)</subject><subject>Side effects</subject><subject>Statistical analysis</subject><subject>Thrombocytopenia</subject><subject>Thrombocytopenia - chemically induced</subject><issn>2045-2322</issn><issn>2045-2322</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNp9ks1u1DAUhSMEolXpC7BAkdiwCdi-dhyvEKooVKrEBtaW41xnPMrEg-0MgqfHnQylZYE3tu79zvHfqaqXlLylBLp3iVOhuoYw3gglKWngSXXOCBcNA8aePlifVZcpbUkZgilO1fPqDLqWQwHOK39tbA4x1SalYL3JONQ_fN7UG9yZHKYwemum2gwHjAnriAX3YU51cPUQl7EIl7wJ0f8qwoM3dd5gbXHO0UzH2j4Gi8MS8UX1zJkp4eVpvqi-XX_8evW5uf3y6ebqw21juWK5YYNFzpXEFqgSvLOkI9yRoQXem74nnXMdyp5YcJyD6ZgTxrQFVEI4VBIuqpvVdwhmq_fR70z8qYPx-lgIcdQmZm8n1EJCLxn2gjrkAMUCwCFtJeMOpGqL1_vVa7_0OxxO93pk-rgz-40ew0HT8kcMgBaHNyeHGL4vmLLe-WRxmsyMYUkaCAcimTqir_9Bt2GJc3mrO4oxKkGyQrGVsjGkFNHdn4YSfZcMvSZDl2ToYzI0FNGrh_e4l_zJQQFgBVJpzSPGv3v_x_Y3MNbEoQ</recordid><startdate>20240420</startdate><enddate>20240420</enddate><creator>Stević, Ivana</creator><creator>Janković, Slobodan M.</creator><creator>Georgiev, Andrijana Milošević</creator><creator>Marinković, Valentina</creator><creator>Lakić, Dragana</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><general>Nature Portfolio</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>88I</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20240420</creationdate><title>Factors associated with hematological adverse reactions of drugs authorized via the centralized procedure</title><author>Stević, Ivana ; Janković, Slobodan M. ; Georgiev, Andrijana Milošević ; Marinković, Valentina ; Lakić, Dragana</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c492t-2dce4497e6319548c0804f0d634babb08ff8e7b0c3f443a82f5aa6548955fe973</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>631/154/1438</topic><topic>631/154/155</topic><topic>692/499</topic><topic>692/700/155</topic><topic>692/700/478/174</topic><topic>692/700/565/2194</topic><topic>Anemia</topic><topic>Anemia - chemically induced</topic><topic>Anemia - drug therapy</topic><topic>Biological products</topic><topic>Biosimilar Pharmaceuticals - adverse effects</topic><topic>Centralized procedure</topic><topic>Drug Approval</topic><topic>Drug-Related Side Effects and Adverse Reactions - epidemiology</topic><topic>Drug-Related Side Effects and Adverse Reactions - etiology</topic><topic>Drugs</topic><topic>Drugs, Essential</topic><topic>Drugs, Generic</topic><topic>Hematological adverse drug reaction</topic><topic>Hematology</topic><topic>Humanities and Social Sciences</topic><topic>Humans</topic><topic>Leukopenia</topic><topic>Leukopenia - chemically induced</topic><topic>multidisciplinary</topic><topic>Pharmaceutical Preparations</topic><topic>Regulatory factors</topic><topic>Science</topic><topic>Science (multidisciplinary)</topic><topic>Side effects</topic><topic>Statistical analysis</topic><topic>Thrombocytopenia</topic><topic>Thrombocytopenia - chemically induced</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Stević, Ivana</creatorcontrib><creatorcontrib>Janković, Slobodan M.</creatorcontrib><creatorcontrib>Georgiev, Andrijana Milošević</creatorcontrib><creatorcontrib>Marinković, Valentina</creatorcontrib><creatorcontrib>Lakić, Dragana</creatorcontrib><collection>SpringerOpen website</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection (ProQuest Medical &amp; Health Databases)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest Science Journals</collection><collection>Biological Science Database</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Scientific reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Stević, Ivana</au><au>Janković, Slobodan M.</au><au>Georgiev, Andrijana Milošević</au><au>Marinković, Valentina</au><au>Lakić, Dragana</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Factors associated with hematological adverse reactions of drugs authorized via the centralized procedure</atitle><jtitle>Scientific reports</jtitle><stitle>Sci Rep</stitle><addtitle>Sci Rep</addtitle><date>2024-04-20</date><risdate>2024</risdate><volume>14</volume><issue>1</issue><spage>9074</spage><epage>9074</epage><pages>9074-9074</pages><artnum>9074</artnum><issn>2045-2322</issn><eissn>2045-2322</eissn><abstract>Serious hematological adverse drug reactions (HADRs) may lead to or prolong hospitalization and even cause death. The aim of this study was to determine the regulatory factors associated with HADRs caused by drugs that were authorized up to July 2023 by the European Medicines Agency (EMA) and to evaluate the frequency of HADRs. Using a cross-sectional approach, the type and frequency of HADRs were collected from the Summaries of Product Characteristics of Drugs Authorized by the EMA and analyzed within proprietary, nonproprietary, and biosimilar/biological frameworks. Multivariate statistical analysis was used to investigate the associations of generic status, biosimilar status, conditional approval, exceptional circumstances, accelerated assessment, orphan drug status, years on the market, administration route, and inclusion on the Essential Medicines List (EML) with HADRs. In total, 54.78% of proprietary drugs were associated with HADRs at any frequency, while anemia, leucopenia, and thrombocytopenia were observed in approximately 36% of the patients. The predictors of any HADR, anemia, and thrombocytopenia of any frequency are generic status, biosimilar status, and inclusion on the EML, while the only protective factor is the administration route. Biosimilars and their originator biologicals have similar frequencies of HADRs; the only exception is somatropin. Knowledge of the regulatory factors associated with HADRs could help clinicians address monitoring issues when new drugs are introduced for the treatment of patients.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>38643204</pmid><doi>10.1038/s41598-024-59710-3</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2045-2322
ispartof Scientific reports, 2024-04, Vol.14 (1), p.9074-9074, Article 9074
issn 2045-2322
2045-2322
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_573b72eb51fe43389533fe16724f3796
source Publicly Available Content (ProQuest); PubMed Central; Free Full-Text Journals in Chemistry; Springer Nature - nature.com Journals - Fully Open Access
subjects 631/154/1438
631/154/155
692/499
692/700/155
692/700/478/174
692/700/565/2194
Anemia
Anemia - chemically induced
Anemia - drug therapy
Biological products
Biosimilar Pharmaceuticals - adverse effects
Centralized procedure
Drug Approval
Drug-Related Side Effects and Adverse Reactions - epidemiology
Drug-Related Side Effects and Adverse Reactions - etiology
Drugs
Drugs, Essential
Drugs, Generic
Hematological adverse drug reaction
Hematology
Humanities and Social Sciences
Humans
Leukopenia
Leukopenia - chemically induced
multidisciplinary
Pharmaceutical Preparations
Regulatory factors
Science
Science (multidisciplinary)
Side effects
Statistical analysis
Thrombocytopenia
Thrombocytopenia - chemically induced
title Factors associated with hematological adverse reactions of drugs authorized via the centralized procedure
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T13%3A13%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Factors%20associated%20with%20hematological%20adverse%20reactions%20of%20drugs%20authorized%20via%20the%20centralized%20procedure&rft.jtitle=Scientific%20reports&rft.au=Stevi%C4%87,%20Ivana&rft.date=2024-04-20&rft.volume=14&rft.issue=1&rft.spage=9074&rft.epage=9074&rft.pages=9074-9074&rft.artnum=9074&rft.issn=2045-2322&rft.eissn=2045-2322&rft_id=info:doi/10.1038/s41598-024-59710-3&rft_dat=%3Cproquest_doaj_%3E3042217372%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c492t-2dce4497e6319548c0804f0d634babb08ff8e7b0c3f443a82f5aa6548955fe973%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3042217372&rft_id=info:pmid/38643204&rfr_iscdi=true